Incidence and Risk of Treatment-Related Mortality with Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Cancer Patients: A Meta-Analysis of 21 Randomized Controlled Trials

BACKGROUND: Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) cetuximab and panitumumab have emerged as an effective targeted therapy in the treatment of cancer patients, but the overall incidence and risk of fatal adverse events (FAEs) associated with these agents is still...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Li, Xing, Shan, Bao-En, Wang, Juan, Xing, Lian-Ping, Guo, Xiao-Jin, Zhang, Yue-Hua, Shi, Peng-Hui, Wang, Zhi-Yu
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2013
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3842967/
https://ncbi.nlm.nih.gov/pubmed/24312376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0081897
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki